Novan, Inc. (NOVN): Price and Financial Metrics


Novan, Inc. (NOVN)

Today's Latest Price: $0.51 USD

0.01 (0.99%)

Updated Sep 28 4:00pm

Add NOVN to Watchlist
Sign Up

Overall POWR Rating


POWR Components:

 Trade Grade  Buy & Hold Grade  Peer Grade  Industry Rank


Industry Rank:

Ranked of 239 in Medical - Pharmaceuticals

See all "A" rated Strong Buy stocks

NOVN Stock Summary

  • Novan Inc's capital turnover -- a measure of revenue relative to shareholder's equity -- is better than just 0.14% of US listed stocks.
  • Equity multiplier, or assets relative to shareholders' equity, comes in at -2.34 for Novan Inc; that's greater than it is for merely 4.51% of US stocks.
  • In terms of volatility of its share price, NOVN is more volatile than 98.19% of stocks we're observing.
  • Stocks with similar financial metrics, market capitalization, and price volatility to Novan Inc are BXC, THC, SEE, MAR, and CSTM.
  • Visit NOVN's SEC page to see the company's official filings. To visit the company's web site, go to www.novan.com.
NOVN Daily Price Range
NOVN 52-Week Price Range

NOVN Stock Price Chart Technical Analysis Charts


NOVN Price/Volume Stats

Current price $0.51 52-week high $3.72
Prev. close $0.51 52-week low $0.22
Day low $0.49 Volume 1,917,107
Day high $0.51 Avg. volume 15,369,874
50-day MA $0.58 Dividend yield N/A
200-day MA $0.66 Market Cap 70.11M

Novan, Inc. (NOVN) Company Bio


Novan, Inc. focuses on the development and commercialization of nitric oxide-based therapies in dermatology. Its lead product candidate is SB204, a cosmetically elegant topical gel that targets multiple mechanisms of action for the treatment of acne vulgaris. The company was founded in 2006 and is based in Durham, North Carolina.


NOVN Latest News Stream


Event/Time News Detail
Loading, please wait...

NOVN Latest Social Stream


Loading social stream, please wait...

View Full NOVN Social Stream

Latest NOVN News From Around the Web

Below are the latest news stories about Novan Inc that investors may wish to consider to help them evaluate NOVN as an investment opportunity.

Novan Strengthens Financial Leadership with Appointments of Chief Financial Officer and Seasoned Industry Executive to Board of Directors

\- John M. Gay, Vice President, Finance and Corporate Controller with over 20 years of financial and accounting experience appointed as Chief Financial Officer - James L. Bierman, seasoned industry executive with extensive strategic financial expertise and business acumen and former CEO, COO and CFO of Owens & Minor, Inc. appointed to Board of Directors MORRISVILLE, N.C., Sept. 24, 2020 (GLOBE NEWSWIRE) -- Novan, Inc. (“the Company” or “Novan”) (Nasdaq: NOVN), today announced the appointment of John M. Gay to serve as the Company’s Chief Financial Officer and the appointment of James L. Bierman to its Board of Directors.Mr. Gay is an accomplished finance and accounting executive with 20 years of professional experience and a demonstrated track record of strategic financial plannin...

Yahoo | September 24, 2020

Novan Inc. and Verrica Pharmaceuticals Participate in Virtual Panel to Discuss Developing Treatments for Molluscum Contagiosum on SNN Network

LOS ANGELES, CA / ACCESSWIRE / September 22, 2020 / SNN Network, The Official Small-, Micro- and Nano-Cap News Source™, today published a new Virtual Panel, titled, "The Pursuit of Molluscum: Beetlejuice and Nobel Prizes", hosted by John Vandermosten, Senior Biotech Analyst at Zack's Small Cap Research.

Yahoo | September 22, 2020

Novan (NOVN) Investor Presentation - Slideshow

The following slide deck was published by Novan, Inc. in conjunction with this event....

SA Transcripts on Seeking Alpha | September 17, 2020

Novan Provides Pipeline and Priority Development Programs Update

\- Lead product candidate, SB206 currently being evaluated in B-SIMPLE4 pivotal Phase 3 study in molluscum contagiosum with topline data targeted for Q2 2021 -\- In vitro assessments of ability of NITRICIL™ to inhibit the replication mechanisms of SARS-COV-2 (COVID-19) underway with key findings targeted before year end -\- Exploratory work to evaluate NITRICIL™ for antimicrobial indications in companion animal health initiated -\- Ongoing review of existing programs and opportunities to expand priority development pipeline - MORRISVILLE, N.C., Sept. 14, 2020 (GLOBE NEWSWIRE) -- Novan, Inc. ("the Company" or "Novan") (Nasdaq: NOVN), today provided a priority pipeline update. In addition to focusing its primary efforts toward SB206, its lead product c...

Yahoo | September 14, 2020

Novan to Present at the H.C. Wainwright 22nd Annual Global Investment Conference

\- Live video webcast with President and CEO, Paula Brown Stafford, on Monday, September 14th at 4:00 PM EDT - MORRISVILLE, N.C., Sept. 09, 2020 (GLOBE NEWSWIRE) -- Novan, Inc. ("the Company" or "Novan") (Nasdaq: NOVN), today announced that Paula Brown Stafford, Chairman, President and Chief Executive Officer of Novan will present at the H.C. Wainwright 22nd Annual Global Investment Conference on Monday, September 14, 2020 at 4:00 PM EDT.In addition to the presentation, management will also be available to participate in virtual one-on-one meetings with qualified members of the investor community who are registered to attend the conference. For more information, please visit the conference website here.A live video webcast of the presentation will be available...

Yahoo | September 9, 2020

Read More 'NOVN' Stories Here

NOVN Price Returns

1-mo 4.29%
3-mo 0.10%
6-mo 15.91%
1-year -80.23%
3-year -90.91%
5-year N/A
YTD -83.86%
2019 280.72%
2018 -80.33%
2017 -84.38%
2016 N/A
2015 N/A

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!



Page generated in 0.7242 seconds.